Last 12 months
Inside the activity.
0 purchase rows · 204 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 17 |
| Dec 2025 | 0 | 26 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 8 |
| Jun 2026 | 0 | 32 |
| Jul 2026 | 0 | 64 |
| Aug 2026 | 0 | 27 |
| Sep 2026 | 0 | 20 |
| Oct 2026 | 0 | 5 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2020 Filed Jun 30, 2020 20:14 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 700 | $200.30 | $140,207.97 |
DisclosureSEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.16 to $200.40, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:14 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 700 | $200.29 | $140,203.98 |
DisclosureSEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.16 to $200.40, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:14 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 679 | $200.27 | $135,984.62 |
DisclosureSEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.00 to $200.40, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:14 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionAmerican Depositary Shares | 2,079 | $160.40 | $333,471.60 |
DisclosureSEC source: 0001651308-20-000087 · wf-form4_159354799249610.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 1,725 | $189.42 | $326,745.02 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 19 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.87 to $189.71, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 3,800 | $188.20 | $715,162.66 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 18 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.87 to $188.83, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 4,115 | $187.10 | $769,914.03 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 17 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,525 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.61 to $187.48, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 4,741 | $186.11 | $882,334.24 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 16 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,640 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.57 to $186.52, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 410 | $188.43 | $77,257.98 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 15 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,381 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.42 to $188.50, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 7,438 | $187.46 | $1,394,334.92 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 14 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,791 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.10 to $188.08, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 4,922 | $186.63 | $918,568.74 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 13 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,229 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.09 to $187.08, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 1,610 | $185.54 | $298,711.99 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,151 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.08 to $186.03, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 690 | $184.56 | $127,348.40 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 11 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,761 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $184.01 to $185.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:12 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 700 | $187.36 | $131,154.03 |
DisclosureSEC source: 0001651308-20-000085 · wf-form4_159304394637720.xml · nonDerivative · entry 11 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F10 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2019. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.19 to $187.85, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:12 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 3,455 | $186.62 | $644,755.52 |
DisclosureSEC source: 0001651308-20-000085 · wf-form4_159304394637720.xml · nonDerivative · entry 10 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 700 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F10 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2019. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.19 to $187.175, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:12 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 1,845 | $185.58 | $342,388.46 |
DisclosureSEC source: 0001651308-20-000085 · wf-form4_159304394637720.xml · nonDerivative · entry 9 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,155 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F10 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2019. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.12 to $186.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 3,095 | $183.72 | $568,600.71 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,451 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.37 to $184.11, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 3,714 | $182.78 | $678,838.98 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,546 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.31 to $183.21, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 1,772 | $181.79 | $322,138.26 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,260 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.31 to $182.26, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 800 | $180.50 | $144,400.96 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,032 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.06 to $180.71, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:23 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 900 | $179.58 | $161,626.23 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,832 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.02 to $179.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:12 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 180 | $183.38 | $33,008.99 |
DisclosureSEC source: 0001651308-20-000085 · wf-form4_159304394637720.xml · nonDerivative · entry 8 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2019. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.37 to $183.40, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:12 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 800 | $182.52 | $146,016.48 |
DisclosureSEC source: 0001651308-20-000085 · wf-form4_159304394637720.xml · nonDerivative · entry 7 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.14 to $183.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:12 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 2,220 | $181.52 | $402,981.73 |
DisclosureSEC source: 0001651308-20-000085 · wf-form4_159304394637720.xml · nonDerivative · entry 6 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 980 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.11 to $182.03, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:12 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 1,800 | $180.37 | $324,665.82 |
DisclosureSEC source: 0001651308-20-000085 · wf-form4_159304394637720.xml · nonDerivative · entry 5 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.06 to $180.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:14 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantShare Option (Right to Buy) · Derivative | 90,766 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001638599-20-000631 · doc4_6762.xml · derivative · entry 1 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 90,766 Underlying: Ordinary Shares · 90,766 shares Expires 2030-06-16 F1 · derivative.exercise_date: 45,383 options ("Share Options") solely exercisable into ordinary shares ("Ordinary Shares") of BeiGene, Ltd. (the "Issuer") each granted to Michael Goller and Ranjeev Krishana, full-time employees of Baker Bros. Advisors LP (the "Adviser") in their capacity as directors of the Issuer. The Share Options with a strike price of $13.42 vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the board of directors of the Issuer (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. The Share Options expire on June 16, 2030. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds. Unvested Share Options are subject to accelerated vesting upon a change in control or certain termination events. F5 · derivative.underlying: Ordinary Shares are convertible into American Depositary Shares on a 13:1 basis. F1 · ownership.nature: 45,383 options ("Share Options") solely exercisable into ordinary shares ("Ordinary Shares") of BeiGene, Ltd. (the "Issuer") each granted to Michael Goller and Ranjeev Krishana, full-time employees of Baker Bros. Advisors LP (the "Adviser") in their capacity as directors of the Issuer. The Share Options with a strike price of $13.42 vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the board of directors of the Issuer (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. The Share Options expire on June 16, 2030. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds. Unvested Share Options are subject to accelerated vesting upon a change in control or certain termination events. F2 · ownership.nature: Michael Goller and Ranjeev Krishana serve on the Board as representatives of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds"). Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all of the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options (i.e. no direct pecuniary interest). F3 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. The Adviser has voting and dispositive power over the Share Options and any Ordinary Shares of the Issuer received as a result of the exercise of Share Options. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Ordinary Shares are convertible into American Depositary Shares on a 13:1 basis. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:06 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
GrantShare Option (Right to Buy) · Derivative | 1,821,976 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000073 · wf-form4_159259715257694.xml · derivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,821,976 Underlying: Ordinary Shares · 1,821,976 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 17, 2020 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon change of control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:13 UTC |
Huang JaneCMO, Hematology
|
GrantShare Option (Right to Buy) · Derivative | 273,286 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000076 · wf-form4_159259757566024.xml · derivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,286 Underlying: Ordinary Shares · 273,286 shares Expires 2030-06-16 F2 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 17, 2021, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. F2 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:13 UTC |
Huang JaneCMO, Hematology
|
GrantOrdinary Shares | 48,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000076 · wf-form4_159259757566024.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,902 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:17 UTC |
Malley ThomasDirector
|
GrantShare Option (Right to Buy) · Derivative | 45,383 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000078 · wf-form4_159259781429439.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 16:31 UTC |
Chen Timothy Yung-ChengDirector
|
GrantShare Option (Right to Buy) · Derivative | 45,383 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000082 · wf-form4_159259869288322.xml · derivative · entry 1 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 16:18 UTC |
su Jingshyh SDirector
|
GrantShare Option (Right to Buy) · Derivative | 45,383 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000079 · wf-form4_159259789928473.xml · derivative · entry 1 su Jingshyh S · CIK 0001315720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:23 UTC |
HOOPER ANTHONY CDirector
|
GrantShare Option (Right to Buy) · Derivative | 45,383 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000081 · wf-form4_159259818823203.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:15 UTC |
Yi QingqingDirector
|
GrantShare Option (Right to Buy) · Derivative | 45,383 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0000902664-20-002459 · ownership.xml · derivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of the issuer's American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of the issuer's American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of the issuer's American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of the issuer's American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:20 UTC |
Glazer Donald W.Director
|
GrantShare Option (Right to Buy) · Derivative | 45,383 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000080 · wf-form4_159259798774597.xml · derivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:15 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
GrantShare Option (Right to Buy) · Derivative | 560,599 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000077 · wf-form4_159259768225614.xml · derivative · entry 1 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,599 Underlying: Ordinary Shares · 560,599 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 17, 2020, and the remaining in 36 equal successive monthly installments, subject to continued service. F2 · derivative.underlying_shares: These securities vest over a four-year period as follows: 25% on the first anniversary of June 17, 2020, and the remaining in 36 equal successive monthly installments, subject to continued service. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:11 UTC |
Liang HowardCFO & Chief Strategy Officer
|
GrantShare Option (Right to Buy) · Derivative | 315,341 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000075 · wf-form4_159259745253027.xml · derivative · entry 2 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,341 Underlying: Ordinary Shares · 315,341 shares Expires 2030-06-16 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 17, 2021, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a sale event. F2 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:11 UTC |
Liang HowardCFO & Chief Strategy Officer
|
GrantOrdinary Shares | 55,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000075 · wf-form4_159259745253027.xml · nonDerivative · entry 1 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,315 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon a sale event. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:09 UTC |
Wu XiaobinPresident & GM China
|
GrantShare Option (Right to Buy) · Derivative | 756,821 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000074 · wf-form4_159259735674939.xml · derivative · entry 4 Wu Xiaobin · CIK 0001739452 · President & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,821 Underlying: Ordinary Shares · 756,821 shares Expires 2030-06-16 F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F3 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F4 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 17, 2021 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. F3 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F3 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:09 UTC |
Wu XiaobinPresident & GM China
|
GrantOrdinary Shares | 134,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000074 · wf-form4_159259735674939.xml · nonDerivative · entry 1 Wu Xiaobin · CIK 0001739452 · President & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514,562 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:14 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 900 | $175.07 | $157,563.00 |
DisclosureSEC source: 0001651308-20-000068 · wf-form4_159199284323253.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.00 to $175.22, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:13 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 631 | $170.84 | $107,800.04 |
DisclosureSEC source: 0001651308-20-000065 · wf-form4_159182358409215.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:17 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 453 | $170.84 | $77,390.52 |
DisclosureSEC source: 0001651308-20-000067 · wf-form4_159182380964210.xml · nonDerivative · entry 2 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. Unvested securities are subject to accelerated vesting upon a sale event. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:15 UTC |
Wu XiaobinPresident & GM China
|
SaleAmerican Depositary Shares | 475 | $171.98 | $81,690.55 |
DisclosureSEC source: 0001651308-20-000066 · wf-form4_159182370219716.xml · nonDerivative · entry 6 Wu Xiaobin · CIK 0001739452 · President & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.73 to $172.46, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:15 UTC |
Wu XiaobinPresident & GM China
|
SaleAmerican Depositary Shares | 1,125 | $171.20 | $192,604.84 |
DisclosureSEC source: 0001651308-20-000066 · wf-form4_159182370219716.xml · nonDerivative · entry 5 Wu Xiaobin · CIK 0001739452 · President & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.5438 to $171.44, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:15 UTC |
Wu XiaobinPresident & GM China
|
SaleAmerican Depositary Shares | 1,200 | $170.02 | $204,022.08 |
DisclosureSEC source: 0001651308-20-000066 · wf-form4_159182370219716.xml · nonDerivative · entry 4 Wu Xiaobin · CIK 0001739452 · President & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.52 to $170.24, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:12 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 200 | $172.46 | $34,492.00 |
DisclosureSEC source: 0001651308-20-000064 · wf-form4_159182350544659.xml · nonDerivative · entry 7 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2019. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:12 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 2,300 | $171.42 | $394,277.04 |
DisclosureSEC source: 0001651308-20-000064 · wf-form4_159182350544659.xml · nonDerivative · entry 6 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.10 to $171.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:12 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 3,500 | $170.48 | $596,685.60 |
DisclosureSEC source: 0001651308-20-000064 · wf-form4_159182350544659.xml · nonDerivative · entry 5 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F4 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.09 to $171.08, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:11 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionShare Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-20-000061 · wf-form4_159112868999563.xml · derivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,575 Underlying: Ordinary Shares · 19,500 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.